19
MSC Medium and Attachment Solution for Serum-free and Xeno-free Expansion of Human Mesenchymal Stem Cells
Xuri™ MSC Medium is a versatile and reliable cell culture product that enables the safe and efficient expansion of human mesenchymal stem cells (hMSC) without the use of animal derived components or undefined serum. It can be used to culture hMSC from a range of sources, including bone marrow, umbilical cord, or adipose tissue.
Compared to serum-facilitated cultivation, Xuri MSC Medium achieves a higher yield of multipotent cells in a single passage, thereby reaching the desired cell dose for patient treatment in a shorter timescale. Removing the need for lengthy batch validation and risk assessment associated with serum also enables a faster and more cost effective process.
Xeno-Free Xuri MSC Attachment Solution is the recommended coating agent for the serum-free expansion of hMSC with Xuri MSC Medium and supports high reproducibility across batches.
Xuri products are supplied with a comprehensive documentation support package that follows USP <1043> requirements applicable to a supplier on ancillary material for cell, gene and tissue-engineered products. All human components included in the product undergo extensive testing in accordance with regulatory requirements.
30237pr@reply-direct.com New Sector Director Role Boosts Offering to Life Sciences and Manufacturing
The multidisciplinary design and engineering firm, Morgan Sindall Professional Services (MSPS), has appointed Brendan Duigenan as Sector Director for Life Sciences and Manufacturing to develop the company’s growing portfolio of work in these and related science, technology and research sectors.
Brendan joined MSPS from HDR and, most recently Perkins+Will, where he was responsible for developing their architectural, engineering and planning businesses within the private and public sectors, including academic institutes and government research bodies. He also has considerable experience in leading process plant and engineering contractors, offering design and project delivery services to manufacturing clients across the industrial, fine chemical, pharmaceutical and biotechnology sectors.
Stuart Parker, Business Development Director for Morgan Sindall Professional Services, said that Brendan’s experience and qualifications will be a further boost to the company’s life sciences, manufacturing and research credentials: “This new role, coupled with Brendan’s technical knowledge and wealth of contracting and consulting experience, will help us to provide dedicated sector support,” he said, “and we look forward to strengthening our relationships and business opportunities with past, current and future clients.”
The company has specialist engineering and design skills in biotechnology, R&D and manufacturing. Working across all containment and processing environments, it has designed over two million square feet of laboratory space for private and public sector clients.
With offices in Manchester, London, Glasgow, Stratford-upon-Avon and Switzerland, Morgan Sindall Professional Services has a wide client base and works across diverse sectors including utility services, alternative energy, transport and public sectors.
30415pr@reply-direct.com
Automated Cell Separation for up to Three Cell Types in a Single Run
New Data Suggests the Possibility of a Simple Blood Test for Cancers
EKF Diagnostics announces that the latest results from its collaboration with the Institute of Life Sciences at the University of Swansea, UK, have continued to confirm the effectiveness of its PointMan™ DNA enrichment technology for isolating and characterising low-level DNA mutations in blood.
DiaSorin has launched LIAISON® Ixt/Arrow CellSep Advanced for the automated isolation of cells directly from whole blood or buffy coat. Based on proven magnetic bead technology, CellSep Advanced can isolate up to 3 cell types per sample in just 32 minutes per cell type, offering significant time savings compared to manual cell separation methods.
CellSep Advanced is designed for use on the LIAISON® Ixt/Arrow instrument for the separation of 1, 2 or 3 cell types in up to 12 samples at a time. Requiring minimal hands-on intervention CellSep Advanced produces good yields of purified cell preparations ready for use in a wide range of downstream applications, including lineage-specific chimerism analysis. The Ixt/Arrow automated platform also minimises human error and ensures reproducibility between runs for consistent and reliable downstream analysis.
“Trials have shown that the performance of CellSep Advanced is equivalent to manual cell separation methods, in terms of cell quality and quantity,” comments Paul Eros, Global Vice President Molecular, DiaSorin. “CellSep Advanced is part of a growing range of cell separation and nucleic acid extraction kits available for use on the LIAISON® Ixt/Arrow instrument, meeting the demands of modern cell analysis applications and ensuring that reliable results are reaching clinicians at the earliest opportunity.”
The LIAISON® Ixt/Arrow instrument can also be used for DNA extraction using the Ixt/Arrow Blood DNA extraction kit, ensuring streamlined processing of samples and, by reducing instrumentation requirements, saving valuable bench space in the laboratory.
29955pr@reply-direct.com
Following work undertaken by the Swansea-based team earlier this year, which successfully detected circulating free DNA (cfDNA) mutations from melanoma patients using PointMan, further studies were carried out on blood samples from endometrial and lung cancer patients, archived in the Wales Cancer Bank. The latest results demonstrated the sensitivity of PointMan in detecting cfDNA mutations – BRAF (endometrial cancer) and EGFR (lung cancer) - which
could therefore serve as a test for these biomarkers in the early detection of these cancers.
Based on the promise of these initial proof-of-concept results, EKF is now sponsoring an MSc studentship to further evaluate the use of PointMan to enrich mutant variants in cfDNA isolated from patients suffering from, or at risk of developing, gynecological cancers. PointMan’s extreme sensitivity offers a unique advantage in the early detection and monitoring of disease progression, as well as in assessing the efficacy of ongoing anti-cancer treatments, without the need for a tissue biopsy.
Based at the Institute of Life Sciences, the ongoing project aims to correlate the presence and abundance of specific mutant variants of known endometrial and ovarian cancer biomarkers in cfDNA from blood samples of patients with established clinical diagnoses for these conditions. Ultimately, the results will establish whether these biomarkers provide a better diagnosis, or enhance current diagnostic tests.
The latest data from Swansea also compliment recent work undertaken using the GILUPI CellCollector™, a device for collecting circulating tumour cells (CTCs) directly from a patient’s blood stream. This highlighted the utility of a blood-based test and critically demonstrated that PointMan can detect just three mutant cells in a background of 1000 wild type cells. A control PCR reaction was unable to achieve such sensitivity, which is important as it reflects the number of mutant cells in a typical patient sample.
31089pr@reply-direct.com
Interested in publishing a Technical Article?
Contact Gwyneth on +44 (0)1727 855574 or email:
gwyneth@intlabmate.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32
